A New Cargo Cult

Again, from Biospace:

PALO ALTO, Calif.--(BUSINESS WIRE)--Intradigm Corporation, a privately held biotechnology drug development company focused on the discovery and development of RNA interference (RNAi) therapeutics for the treatment of diseases with unmet medical needs, has achieved several significant corporate developments. These developments encompass strengthening the senior management team, completing a $16 million Series A financing, and establishing new research and drug development facilities in Palo Alto, CA.

Intradigm was formed in 2000 to develop proprietary nucleic acid delivery technology. The fundamental platform of Intradigm's technology is a ligand-targeted nanoparticle system that is capable of systemic delivery of multiple RNAi molecules targeting different genes.

"The discovery that RNAi can silence gene expression is a major scientific breakthrough, and has led to numerous developments towards the use of this technology as a treatment modality," said Dr. Mohammad Azab, CEO of Intradigm. "However, the translation of that discovery to a therapeutic drug is hampered by lack of effective delivery systems. Intradigm is developing such a system and we intend to aggressively pursue the realization of the therapeutic promise of RNAi using our technology."

New research and drug development facilities in Palo Alto, CA

From the Cargo Cult Scientist:

The company started in 2000, before RNAi had been discovered. When they say, "nucleic acid delivery technology," they are side stepping the fact that they were a gene therapy company. The long suffering gene therepy scientists were given a reprieve with RNAi. They simply morphed into RNAi specialists. Gene therapy, RNAi, what's the difference? It's all nucleic acid magic.

Welcome to the Caro Cults of this blog Intradigm. I await your contributions to this fascinating area of biotechnology. We'll be keeping track of your progress.